Nebulized magnesium sulfate treatment in acute exacerbation of chronic obstructive pulmonary disease

Effect of adjunctive nebulized magnesium sulfate on symptoms and lung volumes, in patients presenting with acute exacerbation of chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016012420024N3

Enrollment

Registered

2016-02-06

Start date

2016-01-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease with acute exacerbation. Chronic obstructive pulmonary disease with acute exacerbation, unspecified

Interventions

Intervention 1: - Drug: 2.5 cc Magnesium Sulfate Vial 20% (Manufactured by Pasteur institute, IRC code: 1228054884) by nebulizer mask, just after performing the tests,. Intervention 2: - Placebo:2.5 c

Treatment - Drugs

Placebo

- Drug: 2.5 cc Magnesium Sulfate Vial 20% (Manufactured by Pasteur institute, IRC code: 1228054884) by nebulizer mask, just after performing the tests,

- Placebo:2.5 cc Sodium Chloride 0.9% (manufactured by Samen co. IRC code:1228065256)

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Known history of chronic obstructive pulmonary disease (COPD) based on previous clinical history and spirometry; 2. Presentating to emergency department with at least two of following symptoms: shortness of breath, increase in the amount of sputum and/or purulent pattern of the sputum; 3. Age>40 years; 4. within 24 h of hospital admission; 5. smoking history > 20 pack.year; Exclusion Criteria: 1. Patient with unstable vital signs; 2. Intubated patient; 3. Associated comorbidity (pneumothorax, pulmonary embolism, pneumonia, acute coronary syndrome, congestive heart failure, neuromuscular disease, active malignancy and etc.); 4. Unconscious patient; 5. Inability to perform spirometry; 6. Nursing/pregnant women; 7. Previous history of allergy to magnesium sulfate;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lung volumes. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: COSMED spirometer.;Arterial oxygen saturation of hemoglobin. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: Pulse oximeter - Beurer.;COPD Assessment Test (CAT) questionnaire, persian version. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: CAT score.	—

Measure

Time frame

Lung volumes. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: COSMED spirometer.;Arterial oxygen saturation of hemoglobin. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: Pulse oximeter - Beurer.;COPD Assessment Test (CAT) questionnaire, persian version. Timepoint: Just before the Magnesium Sulfate/Placebo and again after 90 minutes of administration. Method of measurement: CAT score.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: Discharge documents. Method of measurement: Days of admission.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Soheil Peiman

Department of Internal medicine, Tehran university of medical sciences

s-peiman@tums.ac.ir; soheil_peiman@yahoo.com;+98 21 6693 9922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026